Improving the Diagnosis and Management of Pulmonary Progressive Fibrosis (PPF): A Focus on Systemic Sclerosis Interstitial Lung Disease (SSc-ILD) and Idiopathic Pulmonary Fibrosis (IPF)

Target Audience
This activity is designed to meet the educational needs of rheumatologists, pulmonologists, and advanced practice providers.

Program Overview
This activity features an interactive case-based format where you can review questions to determine best practices in diagnosing and managing PPF, SSc-ILD, and IPF. This session offers real-life examples to help differentiate diseases within the Pulmonary Progressive Fibrosis (PPF) group, such as Idiopathic Pulmonary Fibrosis (IPF) and Systemic Sclerosis Interstitial Lung Disease (SSc-ILD), by focusing on pathophysiology, prevalence, and disease burden.

Participants will learn best practices for diagnosis and routine assessment, while staying updated on ongoing clinical research and treatment guidelines impacting the multidisciplinary management of these diseases.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Differentiate certain diseases within the progressive pulmonary fibrosis (PPF) grouping, such as systemic sclerosis interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF), in terms of their pathophysiology, prevalence, and burden of disease

Identify best practices in the diagnosis and routine assessment of patients with PPF, IPF, and SSc-ILD, in accordance with current guidelines, via real-world patient case scenarios

Recognize ongoing developments in clinical research and treatment guidelines that may impact the multidisciplinary management of these diseases going forward